Page 19 - Read Online

Page 6 of 16 Chen et al. Hepatoma Res 2018;4:72 I http://dx.doi.org/10.20517/2394-5079.2018.103

van Meer et al. [62] , Retro- AFP +/- im- 2005-2012 295 vs. Europe Cirrhosis: BCLC > 9 months 1-year: 68 Surgical
2015 spec- aging +/- 779 (Nether- 97 vs. 60 (P 0: 15 vs. 3 surveil- vs. 55 therapy: 34
tive land) < 0.001) A: 46 vs. 18 lance: 3-year: 47 vs. 25
HBV: 20 vs. B: 21 vs. 14 unadjusted vs. 29 RFA: 23 vs.
14 C: 12 vs. 30 HR 0.55 5-year: 39 7
HCV: 38 vs. (0.42- vs. 22
12 0.73) (P <
Alcohol: 24 0.001)
vs. 30
NAFLD: 7
vs. 20
Thein et al. [22] , Retro- US 2000- 943 vs. Canada Cirrhosis: NA Lead-time Median Curative
2015 spec- 2010 540 52.4 vs. 42 corrected survival (S vs. NS):
b
tive Viral hepa- HR : 0.76 (days, 59.3 vs.
titis: all (0.64- lead-time 41.3 (P <
c
0.91) vs. corrected) : 0.001)
0.86 (0.75- 779 vs. 610
0.98) vs. 478
3-year: 42.6
vs. 35.7 vs.
29.9
5-year: 31.9
vs. 22.4 vs.
20.7
Nusbaum et al. [19] , Retro- AFP +/- im- 2007-2012 126 vs. US Cirrhosis Early-stage Adj HR Overall LTx: 53 vs.
2015 spec- aging 162 (majority (I&II): 92% 0.62 (0.41- survival: 63 23
tive HCV, HBV), vs. 62% (P < 0.94) vs. 49 (P = Surgical
no detailed 0.001) 0.006) (LTx +
data resection):
61 vs. 33 (P
< 0.01)
Wu et al. [23] , Retro- US 2002- 31704 vs. Asia Cirrhosis: NA 5-year Median Curative
d
d
2015 spec- 2007 21119 (Taiwan, 62.5 vs. mortality : survival therapy :
tive China) 38.6 69.9 vs. (lead-time 24.3 vs.
HBV: 28 vs. 71.1 vs. 74.5 corrected, 26.9 vs.
d
27 vs. 77.2 vs. year) : 22.9 vs.
HCV: 30.8 81 2 vs. 1.54 21.3 vs. 18.3
vs. 12 vs. 0.94
Alcohol: 11.1 vs. 0.73 vs.
vs. 5 0.54
Cucchetti et al. [67] , Retro- US +/- AFP 1987- 2012 1084 vs. Europe Cirrhosis: Milan criteria: NA 3-year: 54.4 LTx: 3 vs.
2014 spec- 296 (Italy) all 78.5 vs. 29.7 vs. 24.2 0.7
tive HBV: 10.2 5-year: 31.1 Resection:
vs. 12.8 vs. 12.2 14.8 vs. 13.9
HCV: 61.6 RFA/PEI:
vs. 34.5 41.9 vs. 12.5
Alcohol 8.9
vs. 23
Others 6.8
vs. 13.2
EL-Serag et al. [68] , Retro- AFP + US 1998-2007 580 vs. US HCV: all NA HR: 0.71 3-year: 22 NA
2011 spec- 332 Cirrhosis: (0.62- vs. 13
tive NA 0.82)
Stroffolini et al. [69] , Pro- AFP + US 2008- 257 vs. Europe Cirrhosis: Single tumor: NA NA NA
2011 spec- 2009 154 (Italy) 97.5 vs. 90.1 65.6 vs. 47.1 (P
tive (P = 0.003) < 0.0001)
HBV: 14 vs. Multinodular:
15.1 30.8 vs. 35.3
HCV: 61.6 Diffuse: 3.6 vs.
vs. 46 (P = 17.6
0.01) Vascular inva-
HBV + sion: 9.6 vs.
HCV: 1.3 vs. 26.4
2.2 Metastasis: 2.2
vs. 5.6
Yang et al. [70] , Retro- Imaging (US/ 2007- 136 vs. US Cirrhosis: Milan criteria: NA 10 months: Curative:
2011 spec- CT/MRI) 2009 307 98 vs. 77 63 vs. 20 52.9 vs. 64 vs. 31
tive 33.9
20 months:
25% vs.
13.7
30 months:
9.6 vs. 5.2